Value in Health

Article	Citations
Author Reply	121
When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations	78
CO107 Assessing Short and Long-Term Outcomes in Drug-Associated Acute Kidney Injury	78
EE52 The Burden of Intravenous vs Subcutaneous Oncological Products Application in Honduras	75
CO137 Are Standard Indirect Treatment Comparison Methods Suitable to Compare First-Line Vs Maintenance Therapies? An Assessment of Enfortumab Vedotin + Pembrolizumab Vs Avelumab in Locally Advanced/Me	75
CO67 Network Meta-Analysis to Compare the Efficacy Between Different Classes of PCSK9 Inhibitors, siRNA Vs. PCSK9 mAb, in Asian Patients With Hypercholesterolemia at Increased Cardiovascular Risk	72
EPH156 Multimorbidity and Its Associations with Adverse Cardiovascular Events and Healthcare Costs Among Patients with Atherosclerotic Cardiovascular Disease: A Real-World Evidence Study	70
EE181 Impact of Type 1 Diabetes on Productivity and Out-of-Pocket Costs of Adult Continuous Glucose Monitoring Users in the United States: Results From a Cross-Sectional Survey in the United States	66
EE105 Cost-Effectiveness Analysis of Linperlisib for Relapsed or Refractory Follicular Lymphoma Based on Matching Adjusted Indirect Comparison in China	65
EE266 The Economics Promises of a Cure: Best Practices to Guide Economic Negotiations for the Reimbursement of Curative Therapies for Cancer	63
EE310 The Burden of Blood Transfusions Associated With Lower-Risk Myelodysplastic Syndromes (LR-MDS): Findings From a Survey of Health Care Professionals (HCPs) in Brazil, Germany, and Japan	60
EPH175 Assessment of Streptococcus Pneumoniae as Cause of Acute Otitis Media in Young Children in Colombia: A Prospective Study	56
EE311 Exploring Environmental Impacts of Switching Salmeterol/Fluticasone Propionate (SAL/FP) from Metered Dose Inhaler (MDI) to Dry Powder Inhaler (DPI) in Respiratory Illness in the United Kingdom	54
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China	52
EPH190 Trends and Disparities in Perinatal Health Outcomes Among Women from Refugee Backgrounds in Victoria, Australia: A Population-Based Study	52
EE79 Real-World Clinical and Economic Burden of Primary Biliary Cholangitis in the United States	50
EE258 Cost-Effectiveness of Transcatheter Aortic Valve Implantation (TAVI) for High-Risk Patients in Chile	47
EE226 Productivity Loss Among Persons With Multiple Sclerosis Treated With Ocrelizumab Vs Other Disease-Modifying Therapies	47
EPH115 Sex Differences on Limitations in Physical Functioning and Overall Quality of Life of People Living with Myasthenia Gravis from the MGFA Global MG Patient Registry (MGFAPR) in the US	46
HSD25 Patients’ Rare Disease Diagnoses and Their Impact on Physicians’ Emotions: A Cross-Sectional Study in the United States	44
EPH27 The Efficacy of Interventions Utilized in Communicating Risk Information to Improve Behavioral Outcomes Among Individuals Who Are Genetically Predisposed of Type 2 Diabetes: A Systematic Review	43
PCR222 Comparison of Recanalisation Therapies in Terms of Quality of Life in Ischaemic Stroke Patients in Hungary	42
HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)	42
CO210 An Updated Systematic Review and Network Meta-Analysis on Risks of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis	37
PCR207 Health-Related Quality of Life and Its Associate Factors Among Residents in Tianjin, China: Findings from 2023 National Health Service Survey	37

EPH222 Trends of Mortality Related With Dengue in Colombia 2012-2021	37
RWD135 Right-Sided vs Left-Sided Colorectal Cancer Hospitalization Outcomes in the US	37
SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review	35
P53 Validation of AI-Generated Synthetic Data for Outcomes Research: A Clinico-Genomics Case Study	34
SA13 Approaches to Electronic Health Records Notes Selection: Considerations for Best Practices	34
PT4 Will the IRA's Negotiation Timelines Delay Access to Drugs for Orphan Indications?	34
EE481 Long-Term Cost-Effectiveness of Tirzepatide Versus Placebo for Individuals With Type 2 Diabetes and Obesity	34
CO18 Impact of Empiric Treatment Failure on Healthcare Resource Utilization and Costs Among Females With Uncomplicated Urinary Tract Infections in a US-Based Integrated Health Delivery Network	34
P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States	34
CO72 Investigating Regional Differences in Cardiovascular Outcomes Among Patients Diagnosed with Hypertrophic Cardiomyopathy	33
CO49 Progression of Chronic Kidney Disease Among Older Adults with Hypertension Using Group-Based Trajectory Modeling	33
EE45 Influential Factors on the Economic Justifiable Price: Systematic Investigation of Factors and Mechanisms Beyond the Incremental Cost Effectiveness Ratio	32
EE438 A Budget Impact Model (BIM) for the Introduction of the TEARCARE® System to a United States (US) Health Plan for the Treatment of Meibomian Gland Dysfunction (MGD)-Associated Dry Eye Disease (DE	32
EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population	32
EPH14 Association between the Use of Macrolide Antibiotics and Recurrent Wheezing in Hospitalized Infants with Bronchiolitis	31
PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population	31
OP17 Are Dengue-Related Technological Solutions Evolving to Address the Global Public Health Problem?	30
MT14 Assessing the Association Between Cardiovascular Acoustic Biomarkers and Heart Failure: A Systematic Literature Review	30
RWD50 Progression-Free Survival after First-Line Treatment in Endometrial Cancer Patients: A Real-World Perspective from Brazil and Argentina	30
SA76 A Targeted Literature Review of Economic Evaluations, Health-Related Quality of Life, Healthcare Resource Use, and Costs Associated With Polymyalgia Rheumatica	29
HTA56 ICER Vs NICE – What Are Your Key Considerations for Health Technology Assessments for Rare Disease Therapies? Insights from a Review of Completed Assessments (2017-PRESENT)	28
HPR144 Optimization in Universal Health Coverage Design in South Africa Considering Both Health Outcomes and Health-Induced Poverty Outcomes	28
MSR45 Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients With Atrial Fibrillation and Cancer	28
MSR65 The Benefits of a Complex Identification and Stratification Model for Depression: Insights from a Large Claims Analysis Study	28
EPH211 Treatment Patterns and Clinical Characteristics of Patients Diagnosed with Metastatic NSCLC in Hmo from Colombia: A Real Word Evidence Study	28
RWD141 Assessing the Potential Value of the Flatiron Health Commercial Mortality Data Combined with Publicly Available Death Data for Non-Oncology Research	27
P26 VBA and R to Automate Health Economic Model Programming	27
SA11 Real-World Effectiveness and Safety of First-Line Pembrolizumab Monotherapy for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis	27
PCR42 Health State Utilities in Duchenne Muscular Dystrophy (DMD): A Longitudinal Study Using the EQ5D and Health Utilities Index (HUI)	27
CO121 Analysis of the Burden of Illness, Treatment, and Health Disparities in Amyotrophic Lateral Sclerosis	26
MSR101 Evaluating Pain Scores and Detecting NSCLC Using Named Entity Recognition and Agentic AI in Clinical Texts	26
PCR41 Exploring the Landscape of Patient-Reported Outcomes in PCOS Clinical Trials	26
EE137 Work Productivity Losses of Systemic Lupus Erythematosus in a U.S. Commercially Insured Population	26
HTA59 Revisiting Archetypes: New Archetypes for Strategic Global Value Evidence Planning	26
MSR20 Discordance Between Two Claims-Based Frailty Indices in a Hospitalized Medicare Population	25
RWD108 A1c Improvement After Initiating Real-Time Continuous Glucose Monitoring Among People with Type 2 Diabetes Not on Insulin Therapy	25
EE88 An Economic Model Exploring the Impact of Formulary Restrictions on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation Receiving Direct Oral Anticoagulant	24
EE176 Cost Savings with Treosulfan and Fludarabine Conditioning Regimen vs. RIC (Bu2/Flu and Flu/Mel) and MAC Regimens (Bu4/Flu and Bu4/Cy) in Patients Undergoing Allogeneic HSCT for AML or MDS	24
HPR119 Geographical and Temporal Variations in Availability of National Price Negotiated Novel Anticancer Drugs: A Spatial Statistical Study Based on Two Cross-Sectional Datasets in China	24
EPH10 Investigating the Pain Severity and Frequent Exercise Relationship in United States Adults Using the Medical Expenditure Panel Survey	23
EE165 Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System	23
MT31 Adoption of a Drug Adherence-Enhancing Application To Achieve Optimal Medication Adherence and Blood Pressure Control Among Hypertensive Patients: A Randomized Controlled Trial	23
RWD106 Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US	23
RWD48 Impact of Circulating Tumor DNA (ctDNA) Burden Among Patients with Head and Neck Dquamous Cell Carcinoma (HNSCC) - A RWE Analysis	23
PT5 Disparities in Access to CAR-T treatments: Evidence from 100% Medicare Fee-For-Service and Medicare Advantage Claims Data	23
CO145 Utilizing Machine Learning to Predict Survival Outcomes in Multiple Myeloma Patients with Diabetes: Insights from a 20-Year Cohort Study	23
RWD31 The Role of Real-World Evidence in Breast Cancer Drug Submissions to NICE: Insights and Challenges	23
RWD53 Burden of Illness and Healthcare Resource Utilization (HCRU) for Chronic Obstructive Pulmonary Disease (COPD) in Ontario, Canada	23
HSD52 Understanding Barriers to the Early Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease from the Perspective of Physicians and Patients: Results from a Real-World Survey in Germany	23
EE250 Quantifying Spillover Impacts: Effect of Novel Therapies for IgA Nephropathy on Patients Awaiting Kidney Transplant	22

EE303 The Time Value of Money driven by Early Disease-Modifying Interventions in Degenerative Disease	22
CO21 Real-World Evidence on Clinical Outcomes and Safety of Trastuzumab Biosimilar in Colombian Breast Cancer Patients	22
EE248 Healthcare Resource Utilization of Adult Patients with Obesity Before vs. After GLP-1 Treatment in the United States Elective Outpatient Setting	22
HSD50 Racial/Ethnic Disparities in Veterans' Healthcare Experiences Across VA and Non-VA Settings: An Analysis of the Medical Expenditure Panel Survey (2018-2019)	22
EE256 Cost-Utility Analysis of Lorlatinib in First-Line Treatment of adult patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (aNSCLC) in Colombia	22
EE104 Assessing the Economic Impact of Unused Medications in Acute Disease Management: A Retrospective Study in Algeria	21
CO119 Bridging the Gap between the NAPOLI 3 Trial and Real-World Practice: Real-World Overall Survival (OS) of First-Line (1L) FOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	21
RWD80 Presenteeism in Employees with Chronic Conditions: An Analysis Using Linked Claims and Self-Reported Employee Health Risk Assessment Data	20
EE201 The Impact of Family Spillover Effects in Economic Evaluation for SMA Type 1 Treatments in the United States	20
HSD17 Co-Design of a Discrete Choice Experiment for Revascularization Decisions in Complex Coronary Heart Disease: Importance of Patient Perspectives	20
HSD41 Impact of Racial and Ethnic Disparities on Health-Related Quality of Life in Older Adults With Arthritis in the United States	20
EE411 Estimating the Potential Cost-Effectiveness of Long-Acting Naltrexone versus Oral Naltrexone for Alcohol Use Disorder	20
CO189 Patient- and Observer-Reported Outcomes with Therapeutic Medical Devices in Children and Adolescents with Obesity: A Systematic Literature Review	20
CO86 Comparing Chemotherapy, Monotherapy, and Combination Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer Progression-Free Survival and Overall Survival: Systematic Review and Meta-Analysi	19
PCR101 Association of Chronic Conditions and Medication Burden with Patient Preferences for Long-Acting Antiretroviral Therapy in HIV Treatment	19
Editorial Board	19
HSD96 Conceptualisation and the Role of Market Access in Pharmaceutical Industry: A Qualitative Study	19
PCR100 Development and Validation of Patient-Reported Outcome Measures for Platysma Prominence	18
EPH282 3-Year Healthcare Resource Consumptions of Patients With Immunoglobulin A Nephropathy in a Large Real-World Italian Database	18
CO146 Systematic Literature Review of Hospital Time and Resource Consumption in Subcutaneous and Intravenous Oncologic Biologic Therapies: The Case Study of Atezolizumab From an Italian Perspective	18
HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports	18
HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey	18
PCR237 Patient Activation and Health Outcomes in Spinal Surgery: A Systematic Literature Review of Measures, Effects, and Strategies	18
HPR215 Exploring the Efficacy, Safety, and Regulatory Approval of Priority Reviewed Innovative Drugs in China (2015-2023)	18
PCR147 Treatment Preferences of Patients With Crohn's Disease in Greece: A Cross-Sectional Patient Survey	18
MT60 Artificial Intelligence-Based Tools Designed to Predict Future Mechanical Ventilation and/or Mortality in Hospitalised COVID-19 Patients: A Systematic Literature Review	18
HPR97 More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations	18
MSR165 Evaluating the Effectiveness of AI-Generated vs Real Abstracts in Training Machine Learning Models for Study Selection in Systematic Literature Reviews	18
EE278 A Survey on Japanese Drug Pricing and Treatment Costs of Cancer Chemotherapy Drugs: The Case of Monoclonal Antibodies	18
P54 An Insight Into Real-World Evidence (RWE) As a Component of Submission to NICE & CADTH in the Last 3 Years	18
PCR80 Barriers and Facilitators to the Recruitment and Engagement of Diverse Populations Into Patient Engagement Groups: A Scoping Review	17
RWD156 Patterns of Co-Medications Among People With Schizophrenia in Hong Kong	17
CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study	17
EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia	17
PT37 Comparison of ICD-10 Diagnoses and Longitudinal Estimated Glomerular Filtration Rate (eGFR) in the Detection of Incident Stage 3 Chronic Kidney Disease (CKD): A Retrospective Comparison Study Usi	17
HSD125 Patient Pathways and Healthcare Resources Use in Hepatocellular Carcinoma: Full Analyses of the OPAL Study in Portuguese Population	17
EPH19 Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019	17
EE198 Healthcare Resource Utilization (HCRU) by Patients With Duchenne Muscular Dystrophy (DMD) Using UK Patient Level Data	17
HTA131 Opportunities for Patient Involvement in HTA in the Philippines: Lessons From Guidelines in Europe, North America, and the Asia-Pacific	16
EPH288 Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis	16
EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review	16
EE724 Healthcare Resources Utilization and Costs of Treatment Associated With Anogenital Warts in South Africa: Public and Private Perspective	16
MSR125 AI-Powered Search Strategy Development and Optimization for Systematic Literature Reviews	16
EE375 An Early Health Economic Assessment on a New Method to Estimate 12-Hour Lithium Levels	16
MSR177 Health-Related Quality-of-Life (HRQoL) Assessment for Japanese Cognitive Impairment Associated With Schizophrenia (CIAS)	16
CO79 Effectiveness of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa: Results From a Meta-Analysis	16
HPR87 Poland's Medical Fund Act: Progress of the New Fast-Track TLI Reimbursement Pathway	16
MSR118 Integrating Large Language Models Into an Existing Review Process: Promises and Pitfalls	16
RWD197 Literature Review on the Use of Synthetic Data and AI Advances for Patient-Centered, Sustainable HEOR	16
RWD108 Unveiling the Burden and Impact of Flares in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the Adelphi Real World Disease Specific Program in Europe	16
EPH168 A Descriptive Epidemiological Study of Pediatric Sleep Medications in Japan: A Health Insurance Claims-Based Analysis	16
CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis	16
PCR306 Exploring the Difference That Patient Involvement in HTA Makes in Cancer	15
RWD157 A Real-World Study of Multiple Myeloma Patients With at Least 3 Prior Treatment Lines and Triple Class Exposed Disease in Finland: Outcomes and Need for Healthcare Resource Use	15
HTA246 Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries	15
HSD9 Development of a Framework for a Networked Service Model for the Care of Adults With Rare Bone Conditions: Healthcare Professional Survey for X-Linked Hypophosphataemia (XLH)	15
EE396 Evaluating Long-Term Healthcare Resource Utilization in Biopsy-Confirmed MASLD: A Retrospective Longitudinal Observational Cohort Study in Sweden	15
HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania	15
EE306 Comparison of Methods for Extrapolation of Drug Survival of Biologics in Psoriasis NICE Submission Cost-Effectiveness Analyses	15
CO142 Systematic Literature Review of Real-World Evidence on Overall Survival in Cancer Patients Before and After the Approval of Anti-PD-(L)1 Therapy	15
HTA310 Are Global Health Technology Assessment (HTA) Processes Inclusive and Equitable? A Scoping Review	15
HTA368 Do We Need to Adapt Our Health Technology Assessment (HTA) Systematic Literature Review (SLR) Methods to Comply With the New Joint Clinical Assessment (JCA) SLR Requirements?	15
HPR117 The Economic Burden of Lung Cancer in Greece: A Systematic Review of the Literature	15
HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries	15
HPR225 Impact of the 2021 US Federal X-Waiver Practice Guideline Change on the Prescribing of Buprenorphine and Naltrexone for Treating Opioid Use Disorder in Medicaid Population	14
SA95 A Pragmatic Data Extraction Approach for a Systematic Literature Review for Indirect Treatment Comparison Using Single-Arm Real-World Studies	14
RWD134 Healthcare Pathways and Therapeutic Outcomes of Patients With Spinal Muscular Atrophy: Results From the 12-Year Real-World Study EPI-SMA Based on the French National Healthcare Database (SNDS)	14
EE347 Cost-Effectiveness and Value-Based Price of High-Dose Quadrivalent Influenza Vaccine Among Elderly Populations in Taiwan	14
HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map	14
PCR89 Humanistic Burden of Adrenoleukodystrophy: A Systematic Review	14
PCR174 Importance of Specific Clinical Trial Enrollment Strategies for Native Hawaiian, Pacific Islander, and Asian Patients With Type 2 Diabetes Mellitus	14
HTA308 Analysis of Factors Influencing the Assessment of Metastatic Solid Oncology Products in France: Central Role of Overall Survival (OS) Results and Other Parameters	14
EE830 Exploring Long-Term Durability Assumptions in Cost-Effectiveness Models of Cell and Gene Therapies: A Study of 39 Health Technology Assessments	14
MT2 Real-World Evidence (RWE) in Action: A Review of Australia's Health Technology Assessment (HTA) of Non-Drug Health Technologies	14
PCR39 Health State Utility Values for Patients With Paroxysmal Nocturnal Hemoglobinuria Using EQ-5D-5L	14
EE307 Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration	14
SA53 Epidemiology and Hospital Management of Patients With PROS in France	14
HPR15 Innovative Rebate Management in Oncology Drug Budgets: Streamlining Operations and Enhancing Financial Efficiency Through Technology in Newfoundland and Labrador's Cancer Care Program	14
MSR61 Investigating the Use of the Difference Method for Sampling More Than Two Ordered Variables	14
EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations	13

EPH48 Impact of Influenza-like Illness on Health-Related Quality of Life in Japanese Adults	13
MSR7 Superdeduper: Testing New AI-Powered System for Deduplicating References in Literature Reviews	13
EE393 Economic Impact of COVID-19 Vaccination Programs on Healthcare Workers: A Comparative Model-Based Analysis in the US, UK, Japan, and the Netherlands	13
MSR111 Using Patient-Level Simulation to Estimate Long-Term Survival in Idiopathic Pulmonary Fibrosis	13
PCR277 Patients’ Perspective of the Access to and Quality of Care for Chronic Kidney Disease: Insights From the DISCOVER-CKD Qualitative Study	13
EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar	13
HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges	13
EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal	13
EPH187 Contextualizing the Impact of Multiple Sclerosis (MS) in England Through HES Analysis	12
PCR192 Quality of Life and Its Drivers for Patients Living With Angelman Syndrome (AS): A Systematic Review	12
MSR105 Tackling Rare Events in Network Meta-Analysis: Comparative Performance of Methods for Sparse Safety Outcomes	12
EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective	12
EE362 Tirzepatide in the Treatment of Diabetes: A Systematic Overeview of Economic Evaluations	12
EE765 The Economic Burden of Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease in South Korea and Taiwan	12
SA97 The Relative Effectiveness & Safety of Fluocinolone Acetonide (FAc) and Dexamethasone (DEX) in Diabetic Macular Oedema: A Systematic Review and Matching Adjusted Indirect Treatment Comparison	12
EPH9 Influence of Front Nutritional Labeling on Consumer Choices Related to Ultra-Processed Foods: Scoping Review	12
EPH147 Situational Analysis of Sexual Health in Cartagena and Bolívar, Colombia 2023	12
MSR15 A Novel Crossover Adjustment Analysis of Overall Survival Results From the Phase 3 ClarIDHy Study of Ivosidenib Versus Placebo in Patients With MIDH1 Cholangiocarcinoma	12
CO81 Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data	12
RWD48 Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US	11
MSR50 Use of a Fine-Tuned, Clinical, Bidirectional Transformer (BERT) Large Language Model (LLM) to Classify the Patient and Caregiver Voice Through Their Social Media Health Posts: An Example in Non-	11
HTA86 Indirect Comparisons and Network Meta-Analysis in Spanish Drug Positioning Reports for Price and Financing	11
HPR7 The Discrepancy in Real-World Evidence of New Drug Expenditure Between Actual and Estimated Figures From Manufacturers and Government Agencies in Taiwan	11
P32 Power Implications of Estimator Choice in Synthetic Control Arm Analyses: Results from a Simulation Comparing Average Treatment Effects on the Treated and Untreated Under Propensity Score Weightin	11
RWD86 Healthcare Resource Utilization and Economic Burden of Patients with Gout in the United States	11
RWD116 Reduced Lysosomal Acid Lipase Activity in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Current Evidence and Future Directions	11
Table of Contents	11
PT6 An “R-Shiny” Interface Designed As a One-Stop Solution for All Kinds of Survival Analysis According to NICE Technical Support Documents 14 and 21	11
EE237 The Risk-Based Price: Incorporating Uncertainty and Risk Attitues in Health Technology Pricing	11
Award Winners	11
Editorial Board	11
HTA35 Testing and Piloting of a Value Framework for Diagnostic Technologies in Latin America	11
RWD120 Impact of Healthcare Fragmentation on Survival of Patients with Colorectal Cancer in Colombia	11
EE498 Economic Burden of Interstitial Lung Disease in a Commercially Insured Population with Sjogren's Syndrome in the United States	11
EE504 Leveraging Large Language Models for Conceptualizing Health Economic Models: A Feasibility Study in Oncology	11
SA27 A Non-Systematic Review Evaluating Search Strategies Leveraged in HTA Submissions to NICE	11
MSR42 Time to Stop Sinking Resources Into Developing Predictive Models That Yield No Value: A Framework and Opportunities for Health Economic Methods Development to Reduce Waste in Prediction Model De	11
HSD101 Lack of concordance between real-world treatment patterns and clinical guideline recommendations for metastatic hormone-sensitive prostate cancer (mhspc) patients	11
HSD129 Managing Members with Complex Conditions: A Blue Cross and Blue Shield of Louisiana Program Evaluation	11
EE467 Recovid Study. Cost-Effectivness Analysis of Using Nutridrink 200 ML in the Treatment of COVID-19 in the Hospital	11
SA11 Data Visualization: A Tool to Enhance the Interpretability of Complex and Dense Data Sources	10
EPH158 Years of Life Lost Due to Diabetes Mellitus in Colombia, 1979-2017	10
EPH61 Comparing Fibrosis Staging Approaches Among Patients with Non-Alcoholic Steatohepatitis (NASH) Using Real World Data (RWD)	10
EPH69 Cancers Treatment from Their Perspective: A Qualitative Pilot Study Exploring the Knowledge Attitude and Practice of Folk Medicine Practitioners in a Low-and-Middle-Income-Country	10
EPH139 COVID-19 Vaccine Related Adverse Events in a Population Aged 5–17 Years: A Study of Reports from the VAERS Database	10
HTA70 Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship, a Case Study in Hormone-Relapsed Prostate Cancer	10
RWD118 Rapid Diversification of Immune Checkpoint Inhibitor Usage in Community Health Systems in the US Following New Drug Approvals	10
PCR68 Patient-Provider Communication and Health-Related Quality of Life Among Individuals with Chronic Obstructive Pulmonary Disease in the United States	10
PCR71 Health State Utilities in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib or Sunitinib	10
EPH23 Sociodemographic and Clinical Characteristics of Patients with Atopic Dermatitis in Colombia:Preliminary Results of Rendac	10
HTA48 Minimum Follow-up Time Required for the Detection of the Impact of Treatments on Neuropathic Pain and Gastrointestinal Complaints in Fabry Disease	10
RWD142 Clinical Characteristics of Chinese Patients with Psoriasis Receiving Interleukin-17A Inhibitors: A Single-Center Retrospective Analysis	10
SA40 Indexing Regulatory Documents and Clinical Evidence Publications for Non-Small Cell Lung Cancer (NSCLC) Therapeutics: Establishing a Dataset to Enable the Study of Endpoint Fidelity	10
EE279 A Systematic Literature Review of the Economic Burden in Patients with Myelodysplastic Syndrome	10
EPH67 Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers” of Patients with Breast, Skin, GI, Female, Male, and "Other” Cancers	10
HTA49 Determining Appropriate Health Economic Modeling Approaches in Fabry Disease	10
RWD140 Using Machine Learning to Identify Non-Metastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients from Electronic Health Record Data	10
EE158 Budget Impact of LYBALVI® for the Treatment of Schizophrenia and Bipolar I Disorder from a US Payer Perspective	9
PCR101 Item Response Theory Analysis of the Ilqi	9
EE302 Households Out-of-Pocket Healthcare Expenditures Based on Number of Chronic Conditions in Riyadh, Saudi Arabia: A Quantile Regression Approach	9
PCR102 Leveraging Social Media for Patient Experience Insights in Rare Disease	9
HSD16 Trends in Rheumatology Patient Care and Practice Operations Pre- and Post-COVID-19 Pandemic	9
MSR45 Smooth Algorithm: An Automatic Method to Estimate the Most Likely Drug Combination in Electronic Health Records. Development and Validation Study	9
EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World	9
EE12 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab As a First-Line, 12-Month, Fixed Duration Therapy in Chronic Lymphocytic Leukemia (CLL) in Canada	9
EE395 Cost-Effectiveness of Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-35 Weeks' Gestation	9
HSD5 Changes in COVID-19 Treatment Patterns over the Course of 2020	9
PCR128 Rapid Review: Were There Any Clinical Trials in Non-Muscle Invasive Bladder Cancer That Naturally Adopted the Updated FDA COA Oncology Guidance?	9
EE139 Using a User-Friendly Modeling Tool to Inform and Guide Local Decision-Making for Lynch Syndrome Screening at Healthcare Systems	9
EE303 Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States	9
PCR153 Navigating Barriers to Patient Participation in Qualitative Interviews from International Clinical Trials in Biliary Tract Cancer (BTC)	9
EE198 Cost-Effectiveness of Sacubitril/Valsartan for the Treatment of Essential Hypertension in Chinese Setting	9
EE406 Households Direct Economic Burden Associated with Chronic Non-Communicable Diseases in Saudi Arabia	9
EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience	9
HSD79 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Tardive Dyskinesia	9
HPR59 Targeted and Immunotherapies for Cancer - Reimbursement and Expenditure in a Single-Payer Healthcare System in Bulgaria	9
EE315 Economic Evaluation of Neutralising Monoclonal Antibodies for the Treatment of COVID-19 Positive People in the Community	9
CO87 Treatment Patterns and Costs Associated with Small Cell Lung Cancer in a U.S. Medicare Population	9
PCR151 A Patient-Focused Approach to Understand Unmet Needs in Non-Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)	9
EE257 Cost-Effectiveness Analysis of AI-Assisted Radiological Assessment in Patients With Relapsing Remitting Multiple Sclerosis in the UK	9
MT36 Use of Mobile Health (MHEALTH) Applications in Cancer: A Trend Analysis	9
MSR23 A Machine Learning Approach to Score Employer Groups Based on How Well They Manage Their Specialty Drug Spend	9
MSR30 Modelling Monthly Migraine Day Distribution: A Case Study of Fremanezumab Japanese-Korean Clinical Trials for Migraine Prevention	9
HTA72 Survival Extrapolation for Immuno-Oncology Drugs: Pessimism or Optimism? a Targeted Literature Review and a Validation-Based Case Study	9
EE154 Burden of Invasive Extraintestinal Pathogenic E. coli Disease Among Older Adult Patients Treated in Hospitals in the US	9
PT41 Real-World Evidence in Rare Diseases in France: Treatment Patterns, Healthcare Resource Use, and Related Costs in Von Willebrand Disease (FORvWARD Study)	8
EE705 The Healthcare Resource Utilisation and Associated Costs for Patients with Newly Diagnosed Fragile X Syndrome	8
HTA62 A Systematic Review of the New NICE Highly Specialised Technologies Criteria: How Do NICE Judge Criteria 3 and 4 to be Met?	8
EE31 Identifying Equity-Relevant Subgroup Effects in Alzheimer’s Disease: A Literature Review to Support a Distributional Cost-Effectiveness Analysis	8
EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia	8
RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study	8
HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future	8
EE29 Cost-Effectiveness Analysis and Budgetary Impact of Telescopic Rods for Treatment of Fractures and Correction of Bone Deformities in Children with Osteogenesis Imperfecta in the Brazilian Public	8
Copyright/Subscription	8
CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)	8